Metraipolis › archive › dc_a852eee4a4cc
Real-world validation of ECOG performance status and neutrophil-to-lymphocyte ratio in second-line paclitaxel plus ramucirumab for advanced gastric cancer — Europe PMC PMID:41737601
- Source
- Europe PMC (en)
- Original
- https://europepmc.org/article/MED/41737601
- DOI
- 10.1515/biol-2025-1191
- License (as archived)
- solo-consultazione
- Archived
- 2026-11-07T03:36:30.839Z
- SHA-256 of the archived text
893b417ad76e955ecb716fa882f0a9fd681d0e905d4c3823118b8bd8cce8da67- Stable URL of this page
https://metraipolis.com/documento/dc_a852eee4a4cc
How to cite
Real-world validation of ECOG performance status and neutrophil-to-lymphocyte ratio in second-line paclitaxel plus ramucirumab for advanced gastric cancer — Europe PMC PMID:41737601 — Europe PMC (en), https://europepmc.org/article/MED/41737601 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_a852eee4a4cc (Metraipolis archive dc_a852eee4a4cc, sha256 893b417ad76e955ecb716fa882f0a9fd681d0e905d4c3823118b8bd8cce8da67)
BibTeX
@misc{dca852eee4a4cc,
title = {Real-world validation of ECOG performance status and neutrophil-to-lymphocyte ratio in second-line paclitaxel plus ramucirumab for advanced gastric cancer — Europe PMC PMID:41737601},
howpublished = {Europe PMC (en)},
url = {https://europepmc.org/article/MED/41737601},
note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_a852eee4a4cc; sha256 893b417ad76e955ecb716fa882f0a9fd681d0e905d4c3823118b8bd8cce8da67},
year = {2026}
}Archived text
The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/41737601. Agents can read the archived copy with the MCP tool read_document.